PEI Staff

Arcline agrees Akron Bio sale to MaxCyte in $152m deal

Akron Bio supplies GMP-grade reagents and ancillary materials used in cell therapy manufacturing, including cytokines, growth factors, human plasma-derived products and media.

Hg’s Infitech strikes deal for German financial broker Kees Finanzberater

Kees advises private clients in Braunschweig on insurance, asset building, retirement planning, investments and mortgage financing.

Truelink Capital’s GES buys CSG Creative from National Trade Productions

The agency provides brand strategy, creative, digital and multi-channel marketing services to associations and event organizers.

Interlock Equity seals $525m sale of Lovelytics to CDW

Lovelytics, an Arlington, Virginia-based data and AI services firm, has grown from 60 to more than 600 employees.

Disruption Matters: The Exit Playbook

Disruption Matters is back for its fifth season, and this year's six-part podcast miniseries unpacks the playbook industry leaders are using to navigate the headwinds facing private markets exits, from market timing and buyer psychology, to talent, tech and value creation.

Side Letter: Pricing above par

In today's edition, Trophy assets are commanding premiums in the secondaries market; Moelis taps Lazard for its private capital advisory buildout; Temasek-linked Azalea raises a smaller fund of funds.

Side Letter: Secondaries divergence

In today's edition, Continuation fund activity outstrips traditional secondaries activity; New ESG rules could have a chilling effect on private markets; An APAC rainmaker resurfaces at an international GP.

Side Letter: 'Big, beautiful' opportunities?

The Trump administration's budget bill could further catalyse interest in defence opportunities and AI. Plus: a mixed outlook for emerging VC managers; and NYCERS doubles down on climate investing. Here's today's brief, for our valued subscribers only.

Summer reading: The books LPs are reading right now

Whether your seasonal plans include vacations or staycations, be transported with the faves shared by these private equity investors.

Investcorp on the mid-market sweet spot

Attractive competitive dynamics, value creation potential and monetisation optionality make the mid-market ideal for GP stakes, say Investcorp Strategic Capital Group’s Anthony Maniscalco and Weston Wilkinson.